25
Aug
2022
A Leap for Open Science, Fauci Exits NIH, & Bivalent Boosters on Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2022
Startup Snapshots: Aktis Fetches $84M for Radiopharmaceuticals, 3T Gets $40M for Antigen Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Aug
2022
A Life in Autoimmune Drug Discovery: Jo Viney on The Long Run
Today’s guest on The Long Run is Jo Viney. She is the CEO of Watertown, Mass.-based Seismic Therapeutic. Seismic is working to discover biologic drugs for autoimmune disease. It aims to speed up the process by using machine learning on key aspects – starting with structural biology and including engineering of the protein drugs themselves. Jo has a long track... Read More
11
Aug
2022
Karuna’s Schizophrenia Advance, FDA Clears HER2-Low Drug, & Pfizer Buys GBT
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2022
Assembling Accurate Genomes and Interactomes: Ivan Liachko on The Long Run
Today’s guest on The Long Run is Ivan Liachko. Ivan the founder and CEO of Seattle-based Phase Genomics. First off, Ivan is originally from Kiev, Ukraine. He came with his family to the US at the age of 11, around the time of the fall of the old Soviet Union. When Russia invaded Ukraine back in February, he spoke up... Read More
4
Aug
2022
Alnylam’s Big Day, Amgen Buys ChemoCentryx & a Borisy Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2022
ElevateBio, Boston Children’s Form Startup to Turn iPSCs Into Mature T-cells for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Aug
2022
A Glimpse Into the Adjacent Possible: Incorporating AI Into Medical Science
The implementation of emerging technologies requires front-line users to figure out what to do with the technology – how to adapt the technology to the problems users are actively trying to solve. The most impactful use cases often are not immediately obvious – for example, Edison envisioned the phonograph would be predominantly used to record wills. Moreover, effective adoption typically requires... Read More
26
Jul
2022
The New Frontier of Cytokine Therapies: Engineered Selectivity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jul
2022
CAMP4 Raises $100M to Drug ‘the Dark Side of the Genome’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jul
2022
James Mutamba of Arrakis on Negotiating a Big Amgen Deal at Warp Speed
James Mutamba is the chief business officer of Waltham, Mass.-based Arrakis Therapeutics. It’s a biotech developing small molecules against RNA targets. Arrakis struck its first major pharma partnership in 2020 with Roche. During the JP Morgan Healthcare Conference this past January, Arrakis announced another multi-target collaboration with Amgen to discover and develop small molecule RNA degraders, a new drug class... Read More
14
Jul
2022
Novavax Cleared, Verve’s Gene Editing Milestone, & Third Rock Reaches Out
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jul
2022
Restoring Eyesight in the Developing World: Dr. Sanduk Ruit on The Long Run
Today’s guest on The Long Run is Dr. Sanduk Ruit. He is an ophthalmologist and the founder and executive director of the Tilganga Institute of Ophthalmology. The institute is in Kathmandu, Nepal. Dr. Ruit has restored the eyesight of more than 130,000 people in Asia and Africa. He’s the pioneer of a small-incision form of cataract surgery. Not only was... Read More
10
Jul
2022
Innovators Require An Exception-Oriented Mindset
Living in innovative domains like biomedical research requires an appreciation for the exceptional, the outlier. You might even argue that the goal of innovators – at least those who hope to see their ideas gain acceptance, or their inventions adopted – is to institutionalize the exceptional and make it routine. In the Perez model of technology adoption, this is the... Read More
7
Jul
2022
Merck Circles Seagen, Arch Triples Down & Novartis Cuts 8,000 Jobs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2022
An Open Letter from Female Biotech Leaders on Post-Roe America
[Editor’s Note: this letter was drafted by female biotech leaders in response to the Supreme Court’s Dobbs decision. It was co-signed by more than 65 female biotech executives as of July 1. They’re listed at the end.] Friends and colleagues, legislators and elected officials We join the resounding millions in chorus to express our profound dismay and disappointment at the... Read More
29
Jun
2022
Recode Therapeutics Pockets Extra $120M for Targeted Genetic Medicine Delivery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jun
2022
How Grace Science Built a Community Into a Company
Matt Wilsey, CEO of Grace Science, once said, “You may have a plan set out for your career and your family, but life doesn’t always turn out that way…you have to make the most of it…turn the lemons into lemonade.” It is a fitting description for a person who has made several shifts on a quest to cure a rare... Read More
27
Jun
2022
Nucleate Doubles in Size, Enabling Young Scientists’ Entrepreneurial Dreams
Academia has a tradition of doing nothing, or next to nothing, to educate and encourage young people to learn about entrepreneurship. But whether academia wants it or not, it’s coming. Young scientists are taking matters into their own hands, organizing themselves in many major research hubs. Nucleate, the nonprofit providing free resources to empower a new generation of biotech entrepreneurs,... Read More
27
Jun
2022
What We Saw at BIO: The Second Hurdle
More than 14,000 people attended the annual #BIO22 meeting in San Diego, meaning there are at least 14,000 versions of what happened. But unless you have the emotional intelligence of a rock, you felt the unease, if not outright panic, of an industry with a fast-evaporating cash runway. No one really knows what to do about it. If they say... Read More